Abstract
The opioid agonist-antagonist pentazocine (1–30 mg/kg) and the partial agonist buprenorphine (0.05–0.25 mg/kg) were tested, alone or in combination with the histamine H1-receptor antagonist tripelennamine (1, 2.5, 5 or 10 mg/kg), on locomotor activity in mice of the CD-1 strain. When given alone, pentazocine produced slight and non-dose-related activity increments, while buprenorphine induced strong and dose-related locomotor stimulation. Tripelennamine slightly increased activity by itself and enhanced buprenorphine-, but not pentazocine-induced hyperactivity. The results are discussed in relation to the hypothesis that antihistaminic agents specifically interfere with locomotor effects of opioids.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bluhm RE, Evans MA, Zsigmond EK (1983) Analgesic potentiation and the distribution of morphine in the presence of tripelennamine in mice. Life Sci [Suppl I] 33:673–676
Bovet D, Bovet-Nitti F, Oliverio A (1969) Genetic aspects of learning and memory in mice. Science 163:139–149
Castellano C, Pavone F (1985) Effects of bremazocine on locomotor activity in DBA/2 and C57BL/6 mice. Arch Int Pharmacodyn 278:45–52
Filibeck U, Castellano C, Oliverio A (1981) Differential effects of opiate agonists-antagonists on morphine-induced hyperexcitability and analgesia in mice. Psychopharmacology 73:134–136
Goldberg SR, Spealman RD, Shannon HE (1982) Psychotropic effects of opioids and opioid antagonists. In: Hoffmeister F, Stille G (eds) Psychotropic agents, Part III: Alcohol and psychotomimetics, psychotropic effects of central acting drugs. Springer, Berlin, pp 269–304
Grosset D, Wallace S, Picker M, Poling A (1984) Tripelennamine and pentazocine alone and in combination: effects on interresponse-time-greater-than-t responding of rats. Pharmacol Biochem Behav 20:697–700
Jaffe JH, Martin WR (1985) Opioid analgesics and antagonists. In: Goodman Gilman A, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics, 7th edn. Macmillan, New York, pp 491–531
Jasinski DR, Johnson RE, Henningfield JE (1984) Abuse liability assessment in human subjects. TIPS 5:196–200
Oliverio A, Castellano C (1974) Genotype-dependent sensitivity and tolerance to morphine and heroin: dissociation between opiate-induced running and analgesia in the mouse. Psychopharmacologia 39:13–22
Oliverio A, Castellano C, Puglisi-Allegra S (1984) Psychobiology of opioids. Int Rev Neurobiol 25:277–337
Sansone M, Hano J (1979) Enhancement by chlordiazepoxide of the anticholinergic-induced locomotor stimulation in mice. Psychopharmacology 64:181–184
Sansone M, Castellano C, D'Amato FR (1986a) Enhancement of morphine-induced hyperactivity by antihistaminic drugs in mice. Arch Int Pharmacodyn 284:239–245
Sansone M, Renzi P, Vetulani J (1986b) Facilitation of stimulatory effect of chlordiazepoxide-amphetamine combination by subacute administration of chlordiazepoxide in mice. Psychopharmacology 89:52–54
Sansone M, D'Udine B, Renzi P, Vetulani J (1987) Antihistaminics enhance morphine-, but not amphetamine and scopolamine-induced hyperactivity in mice. Psychopharmacology 93:155–157
Siegel S (1956) Non-parametric statistics for the behavioural sciences. McGraw Hill, New York
Shannon HE, Su TP (1982) Effects of the combination of tripelennamine and pentazocine at the behavioral and molecular levels. Pharmacol Biochem Behav 17:789–795
Vetulani J, D'Udine B, Sansone M (1988) A toggle-floor box: the reliability of crossings in the evaluation of drug-induced locomotor changes in mice. Pol J Pharmacol Pharm 39 (in press)
Yeh SY (1986) The effect of anthistaminic drugs on pentazocine antinociception in the rat. Pharmacol Biochem Behav 24:925–930
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sansone, M., Castellano, C. & Libri, V. Tripelennamine enhances buprenorphine-, but not pentazocine-induced hyperactivity in mice. Psychopharmacology 95, 176–179 (1988). https://doi.org/10.1007/BF00174505
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00174505